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Abstract
Background: Endogenously produced interferons can regulate the growth of melanoma cells and are
administered exogenously as therapeutic agents to patients with advanced cancer. We investigated the role of
negative regulators of interferon signaling known as suppressors of cytokine signaling (SOCS) in mediating
interferon-resistance in human melanoma cells.
Methods: Basal and interferon-alpha (IFN-a) or interferon-gamma (IFN-g)-induced expression of SOCS1 and SOCS3
proteins was evaluated by immunoblot analysis in a panel of n = 10 metastatic human melanoma cell lines, in
human embryonic melanocytes (HEM), and radial or vertical growth phase melanoma cells. Over-expression of
SOCS1 and SOCS3 proteins in melanoma cells was achieved using the PINCO retroviral vector, while siRNA were
used to inhibit SOCS1 and SOCS3 expression. Tyr
701-phosphorylated STAT1 (P-STAT1) was measured by intracellular
flow cytometry and IFN-stimulated gene expression was measured by Real Time PCR.
Results: SOCS1 and SOCS3 proteins were expressed at basal levels in melanocytes and in all melanoma cell lines
examined. Expression of the SOCS1 and SOCS3 proteins was also enhanced following stimulation of a subset of
cell lines with IFN-a or IFN-g. Over-expression of SOCS proteins in melanoma cell lines led to significant inhibition
of Tyr
701-phosphorylated STAT1 (P-STAT1) and gene expression following stimulation with IFN-a (IFIT2, OAS-1, ISG-
15) or IFN-g (IRF1). Conversely, siRNA inhibition of SOCS1 and SOCS3 expression in melanoma cells enhanced their
responsiveness to interferon stimulation.
Conclusions: These data demonstrate that SOCS proteins are expressed in human melanoma cell lines and their
modulation can influence the responsiveness of melanoma cells to IFN-a and IFN-g.
Background
Endogenously produced cytokines of the type I and type II
interferon families are critical for the recognition of devel-
oping tumors by the immune system [1]. Recent evidence
has demonstrated that the actions of endogenous type I
interferons (e.g. IFN-a,I F N - b) are essential for the
immune surveillance of tumors by their direct actions on
host immune cells [2]. Interferon-gamma (IFN-g), a type II
interferon, has also been shown to act directly upon malig-
nant cells and thereby render them more immunogenic [3].
In addition to the role of endogenous IFNs in regulat-
ing tumor growth, IFN-a is administered to patients
with metastatic disease. It is presently the only therapy
approved for use as an adjuvant following surgical resec-
tion of high-risk melanoma lesions [4-8]. There is evi-
dence that the immunostimulatory effects of IFN-a
contribute to its anti-tumor activity [9-11] but exogen-
ous IFN-a can also exert direct anti-proliferative, anti-
angiogenic and pro-apoptotic effects on melanoma cells
[12-15]. The predominant signal transduction pathway
activated in response to both IFN-a and IFN-g is the
Janus kinase-signal transducer and activator of tran-
scription (Jak-STAT) pathway (Reviewed in [16,17]. Our
group has previously demonstrated that IFN-a induced
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highly variable, and, in some cases, significantly attenu-
ated [18]. Interestingly, the expression of key signaling
proteins important for IFN-a-responsiveness was intact
in these IFN-resistant melanoma cells, suggesting that
negative regulatory pathways for IFN-induced signal
transduction might be operative.
One such negative regulatory pathway is a class of
proteins called the suppressors of cytokine signaling
(SOCS). The SOCS proteins consist of eight structurally
related family members, SOCS1-7 and CIS (cytokine-
inducible SH2-containing protein). These proteins con-
tain a central Src-homology 2 (SH2) domain and a con-
served C-terminal domain termed the SOCS box [19].
SOCS proteins can inhibit cytokine-induced signal
transduction (Reviewed in [20] by multiple mechanisms
including: 1) binding to phosphorylated tyrosine resi-
dues; 2) blocking access of transcription factors to their
receptor sites; or 3) SOCS box-targeting of bound pro-
teins for proteasomal degradation [21].
Expression of SOCS1 and SOCS3 has been reported in
melanoma cell lines and in surgical specimens obtained
from malignant melanoma patients where it indicates a
poor-prognosis [22]. However, the functional effects of
SOCS expression on the response of human melanoma
cells to interferons has only been evaluated in a limited
number of studies [23-25]. We hypothesized that
SOCS1 and SOCS3 proteins may down-regulate the bio-
logical response of melanoma cells to endogenous or
exogenously administered interferons.
The present study demonstrates that SOCS1 and
SOCS3 proteins were expressed in a panel of melanoma
cell lines from various stages of disease and in melano-
cytes. IFN-a and IFN-g treatment led to further
increases SOCS1 and SOCS3 expression in some human
melanoma cell lines. Furthermore, over-expression of
SOCS1 and SOCS3 expression led to a significant
reduction in IFN-induced STAT1 phosphorylation and
gene expression. Conversely siRNA-mediated inhibition
of SOCS1 and SOCS3 expression enhanced the inter-
feron-responsiveness of human melanoma cells. These
data provide additional evidence that SOCS proteins
regulate the direct actions of interferons on melanoma
cells.
Methods
Reagents and Cell Lines
Recombinant human (hu) IFN-a2b (specific activity of
2×1 0
8 IU/mg) was purchased from Schering-Plough,
Inc. (Kenilworth, NJ). The HT144, Hs294T, SK-MEL-5
and A375 human melanoma cell lines were purchased
from the American Type Culture Collection (Manassass,
VA). The 1106 MEL, 18105 MEL, MEL-39, 1174 MEL,
FO1 and 1259 MEL human melanoma cell lines were
obtained from Dr. Soldano Ferrone (University of Pitts-
burgh Cancer Institute, Pittsburgh, PA). The radial
growth phase WM 1552c and vertical growth phase
WM 793b human melanoma cell lines were provided by
Dr. M. Herlyn (Wistar Institute, Philadelphia, PA) and
cultured as described [26]. Human embryonic melano-
cytes were purchased from ScienCell Research Labora-
tories (Carlsbad, CA) and cultured per manufacturer’s
recommendations. All studies were conducted with the
approval of The Ohio State University Institutional Bio-
safety Committee.
Immunoblot Analysis
Expression of SOCS1 and SOCS3 proteins in melanoma
cell lines was confirmed via immunoblot analysis with
antibodies directed against SOCS1, SOCS3 (Abcam,
Cambridge, UK), phosphorylated STAT3 (Tyr705),
STAT3 (Cell Signaling Technology, Inc., Danvers, MA),
or b-actin as previously described [27].
Flow Cytometric Analysis of Phosphorylated STAT1
(P-STAT1)
Phosphorylation of STAT1 at Tyr
701 was measured
using an intracellular flow cytometric assay as previously
described; with modifications [28]. To measure STAT1
phosphorylation in retroviral-transduced cells, a goat
anti-rabbit APC-conjugated secondary Ab was employed
(Molecular Probes, Eugene, OR). Amplified fluorescence
signals were expressed as specific fluorescence (Fsp = Ft
-Fb), where Ft represents the median value of total stain-
ing, and Fb represents the median value of background
staining (obtained by staining with the isotype control
Ab) [28].
Real Time RT-PCR
Real-time reverse transcription-polymerase chain reac-
tion (RT-PCR) was used to quantitate transcript levels
of the IFN-a stimulated genes ISG-15 and IFIT2 or
IFN-g-stimulated gene, IRF1 in melanoma cell cultures
as previously described [28,29]. Briefly, melanoma cells
were treated with IFN-a (10
4 U/mL), IFN-g (1 ng/mL)
or PBS for 4 hours. Total RNA was then isolated using
the RNeasy RNA Isolation Kit (Qiagen, Valencia, CA),
quantitated, and converted to cDNA using random hex-
amers as primers for first-strand synthesis. Two microli-
ters of the resulting cDNA was used as a template to
measure the levels of mRNA for ISG expression by
Real-time RT-PCR with pre-designed primer/probe sets
(Assays On Demand; Applied Biosystems, Foster City,
CA) and 2× TaqMan Universal PCR Master Mix
(Applied Biosystems) per the manufacturer’s recommen-
dations. Pre-designed primer/probe sets for human b-
actin were used as an internal control in each reaction
well (Applied Biosystems) and data was analyzed using
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Biosystems).
SOCS Over-expressing Retroviral Constructs
The PINCO retroviral transfer plasmid, originally from
the laboratory of Dr. P.G. Pelicci (Grignani et al., 1998),
was obtained through the courtesy of Dr. Martin Sattler
(Dana Farber Cancer Institute, Boston, MA). This retro-
viral vector permits the expression of a gene of interest
from the 5’ long terminal repeat (LTR) as well as the
enhanced green fluorescent protein (EGFP) from an
internal cytomegalovirus (CMV) immediate early promo-
ter. The development of PINCO-based retroviral con-
structs that over-express SOCS1 and SOCS3 proteins has
been previously described by our group [30,31]. SOCS1-,
and SOCS3-overexpressing retroviral supernatants were
generated by transient transfection of the Phoneix-
Ampho packaging cell line with appropriate PINCO-
SOCS expression plasmid DNA and 0.9 μg of a plasmid
DNA expressing the VSV-G protein (pVSV-G) using the
ProFection® Mammalian Transfection System-Calcium
Phosphate kit according to manufacturer’s instructions
(Promega, Madison, WI) as previously described [31].
Human melanoma cell lines (HT144, 1259 MEL) were
transduced with the resulting SOCS-over-expressing ret-
roviral constructs as previously described [31].
Inhibition of SOCS1 and SOCS3 Using Small Inhibitory
RNA
Silencing of SOCS1 and SOCS3 expression was accom-
plished using pSilencer siRNA expression vectors (Invi-
trogen). siRNA oligonucleotides that target SOCS1 (5’-
CTGGTTGTTGTAGCAGCTTAA-3’)a n dS O C S 3( 5 ’-
TCGGGAGTTCCTGGACCAGTA-3’) sequences were
cloned into the pSilencer vector per manufacturer’s
recommendations. Briefly, 1259 MEL melanoma cells
were transfected with 2 μg siRNA encoding plasmids or
pSilencer vector alone (negative control) via electropora-
tion using the Amaxa Nucelofector device and cell-spe-
cific nucleofector reagent (Amaxa, Inc., Gaithersburg,
MD) according to the manufacturer’s recommendations.
Statistical Methods
Mixed effects regression models were used to analyze
the experimental outcomes, including a random effect
for each experiment. The outcomes of specific fluores-
cence and fold change in gene expression were both
log-transformed to meet the necessary model assump-
tions of normality and constant variance. A Tukey-Kra-
mer adjustment for multiple comparisons was used to
calculate the p-values when comparing groups within
the same experiment [32]. Adjusted p-values less than
0.05 were considered statistically significant.
Results
Melanoma Cell Lines Express SOCS1 and SOCS3 Proteins
The baseline expression of SOCS1 and SOCS3 protein
was measured in a panel of n = 10 human metastatic
melanoma cell lines by immunoblot analysis. These data
revealed that all lines expressed both SOCS1 and
SOCS3 proteins (Figure 1a). Of note, pre-incubation of
primary antibody with commercially available SOCS-
specific peptide competitors (Abcam, Inc.) eliminated
SOCS3 specific immunoreactivity (Data not shown).
Immunoblot analysis in representative cell lines was
subsequently used to evaluate the effects of IFN-a and
IFN-g stimulation on SOCS1 and SOCS3 protein
expression in vitro (Figure 1b). Immunoblot analysis
revealed an induction of SOCS1 and SOCS3 proteins in
some melanoma cell lines following a four hour stimula-
tion with IFN-a (10
4 U/mL) or IFN-g (10 ng/mL). The
IFN-induced expression of SOCS1 and SOCS3 proteins
within individual cell lines was variable. For example,
IFN-a and IFN-g induced SOCS3 protein expression in
the A375 melanoma cell line while both SOCS1 and
SOCS3 proteins were upregulated in the HT144 cell line
(Figure 1b). In contrast, neither SOCS1 nor SOCS3 pro-
teins were further upregulated in the 1259 MEL cell line
following IFN stimulation. To determine whether SOCS
protein expression might be restricted to melanoma
cells at a particular stage of development, we conducted
similar experiments in human embryonic melanocytes
(HEM) and in the WM793b and WM1552c human mel-
anoma cell lines. These two cell lines are derived from
vertical and radial growth phase melanoma cells, respec-
tively. SOCS1 and SOCS3 were expressed at basal levels
in each of these cell types (Figure 1c). Treatment with
IFN-a or IFN-g did not upregulate SOCS1 expression in
any of these cell lines, while SOCS3 was upregulated by
IFN-g only in the WM1552c radial growth phase cell
line.
Phosphorylated STAT3 expression in human melanoma
cell lines
The STAT3 transcription factor promotes a metastatic
phenotype and has been shown to be constitutively
phosphorylated in human melanoma cell lines. Impor-
tantly, STAT3 is also sensitive to inhibition by SOCS
proteins [33] and prior studies in melanoma brain
metastases have suggested that loss of SOCS1 expres-
sion could promote metastasis via elevated STAT3 sig-
naling. We therefore analyzed pSTAT3 levels in order
to determine whether SOCS1 protein expression and
basal STAT3 phosphorylation were associated in the
panel of melanoma cell lines. These data indicated that
basal STAT3 phosphorylation (at Tyr
705)a n dS O C S 1
expression were present concurrently (Figure 1d). These
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the level of basal pSTAT3.
Inhibition of IFN-Responsiveness in Melanoma Cell Lines
that Over-express SOCS Constructs
To further validate the role of SOCS protein expression
in regulating IFN-responsiveness of representative
human melanoma cell lines (HT144, 1259 MEL), we
employed retroviral constructs that expressed SOCS1
and SOCS3. Non-transduced cells and cells transduced
with the empty PINCO retroviral vector were used as
controls in these assays. Twenty-four hours following
transduction of human melanoma cell lines with the
SOCS1 and SOCS3-expressing retroviral constructs or
empty PINCO vector, the expression of EGFP was con-
firmed in each cell line by flow cytometry (Figure 2a).
EGFP
+ cells were sorted by flow cytometry and cultured
for use in subsequent experiments. Transduced mela-
noma cell lines over-expressed SOCS1 and SOCS3 pro-
teins as determined by immunoblot analysis (Figure 2b-
c). No increase in SOCS1 or SOCS3 expression was
observed in any melanoma cell line transduced with the
empty PINCO vector. Analysis of STAT1 phosphoryla-
tion by flow cytometry indicated that IFN-a-induced
signal transduction was significantly inhibited in HT144
and 1259 MEL cells that over-expressed SOCS1 as
compared to either parental cells or those transduced
with the empty PINCO vector (all p-values = 0.019).
Figure 1 SOCS1, SOCS3 and STAT3 expression in melanoma cell lines. (a) Basal expression of SOCS1 and SOCS3 proteins in a panel of n =
10 human melanoma cell lines was measured by immunoblot analysis. b-actin served as a control for equal loading. Basal and IFN-induced
SOCS1 and SOCS3 expression was evaluated in (b) human metastatic melanoma cell lines and (c) human embryonic melanocytes (HEM) or
vertical (WM793b) and radial (WM1552c) human melanoma cell lines by immunoblot following treatment of human melanoma cell lines with
IFN-a (4 hours; 10
4U/mL) and IFN-g (4 hours; 10 ng/mL). A375 cells were used as a positive control for SOCS1 and SOCS3 expression (Pos. Ctrl).
Immunoblot data shown are representative from at least 3 independent experiments. (d) Constitutive phosphorylation of STAT3 was evaluated
in this panel of cell lines by immunoblot analysis. Antibodies directed against STAT3 protein and b-actin were included to control for variations
in STAT3 across cell lines and equal loading, respectively.
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in IFN-a-induced signal transduction in the 1259 MEL
cell line (p = 0.0052), but this did not reach statistical
significance in the HT144 cell line (Figure 3a-b; p =
0.087). Similar results were obtained for IFN-g-induced
activation of STAT1 (Figure 3c-d). IFN-a and IFN-g
responsiveness was most inhibited by over-expression of
SOCS1 as compared to SOCS3. As expected, SOCS1
over-expression significantly reduced the transcription
of IFN-a regulated genes (ISG-15 and OAS1) and the
IFN-g induced gene IRF1 in these cell lines (Figure 4a-d;
all p-values ≤ 0.01). Similar to our signal transduction
data, over-expression of SOCS3 in the 1259 MEL cell
line produced a statistically significant inhibition of IFN-
stimulated gene expression (all p-values ≤ 0.0049) but
results for HT144 were mixed. A significant difference
was observed for expression of ISG-15 in the HT144
cell line (p = 0.0144), but not for OAS-1 (p = 0.0511) or
IRF1 (p = 0.49).
Interferon-Responsiveness in Melanoma Cell Lines
Transfected With SOCS1 or SOCS3-targeted siRNA
constructs
The interferon-responsiveness of SOCS1 and SOCS3-
positive 1259 MEL melanoma cells transfected with a
vector expressing siRNA constructs targeting SOCS1 or
SOCS3 was next investigated. Cells transfected with an
empty vector served as negative controls in these stu-
dies. Transfection efficiency was typically > 90% as
determined by transfection of cells with a GFP-expres-
sing plasmid in parallel (data not shown). Reduced levels
of SOCS1 and SOCS3 transcript were confirmed by Real
Time PCR (Figure 5a-b). We proceeded to test whether
the reduced level of SOCS expression would affect the
IFN-responsiveness of melanoma cells. Due to high
basal expression, complete knockdown of SOCS1 and
SOCS3 in these cells was difficult to achieve. However,
their reduced expression following transfection of 1259
MEL cells with SOCS1 or SOCS3 siRNA led to consis-
tent increases in IFN-a or IFN-g-induced P-STAT1 as
compared to cells transfected with control siRNA (Fig-
ure 5c). Transcription of IFN-a-induced genes (IFIT2,
ISG-15) was tested by Real Time PCR and found to be
significantly increased in cells transfected with SOCS1-
siRNA or SOCS3siRNA (Figure 5d; all p-values < 0.005).
Discussion
I nt h ep r e s e n ts t u d yw eh a v ed e m o n s t r a t e dt h a th u m a n
melanoma cell lines express basal levels of SOCS1 and
SOCS3 and that these proteins are further increased
upon stimulation with type I and type II IFNs. Over-
Figure 2 Retroviral mediated over-expression of SOCS1 and
SOCS3. GFP expression was evaluated by flow cytometry in
melanoma cells stably transduced with PINCO retroviral vectors
over-expressing SOCS1 or SOCS3. A representative example is
shown in (a). Over-expression of (b) SOCS1 and (c) SOCS3 at the
protein level was confirmed by immunoblot analysis. Membranes
were stripped and re-probed with b-actin as a control for equal
loading.
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cell lines led to a significant decrease in the IFN-respon-
siveness of melanoma cells. Conversely, siRNA-mediated
reduction of SOCS1 and SOCS3 led to an increase in
IFN-responsiveness. These data support a role for basal
expression of SOCS1 and SOCS3 as contributors to
IFN-resistance in human melanoma cells.
Maximizing the direct effects of type I and type II
IFNs on melanoma tumors is a challenge due to the
genetic heterogeneity of these cell types. Indeed, defects
in key components of IFN-a induced signal transduc-
tion pathways have been noted in several malignant
melanoma cell lines. For example, tumor cell lines with
defects in STAT1, IRF9 and Jak1 have been identified
and have been found to have reduced in vitro
responsiveness to IFN-a [14,34,35]. Previous reports
from our group and others have also suggested that the
direct actions of IFN-a on melanoma cells are highly
variable and often attenuated, even when the expression
of Jak-STAT intermediates were intact [18,36,37]. Data
from the present study extends these initial observations
and further suggests that expression of SOCS proteins
represent a means by which melanoma cells can achieve
IFN-resistance.
In agreement with the present study, Li et al.h a v e
shown that SOCS1 and SOCS3 proteins were expressed
in both human melanoma cell lines and primary tumors
from melanoma patients. In this prior study, SOCS1
expression in primary tumors from melanoma patients
was thought to be an indicator of poor prognosis as it
Figure 3 Reduced IFN-induced P-STAT1 in melanoma cells over-expressing SOCS1 and SOCS3. Phosphorylated STAT1 was measured by
flow cytometry following a 15-minute stimulation of SOCS1- and SOCS3-over-expressing cell lines with (a, b) IFN-a or (c, d) IFN-g. Both non-
transduced and empty vector transduced melanoma cell lines served as negative controls in these experiments. Error bars represent standard
deviation and are derived from triplicate experiments. * Denotes p < 0.05 as compared to empty vector transduced cells.
Lesinski et al. BMC Cancer 2010, 10:142
http://www.biomedcentral.com/1471-2407/10/142
Page 6 of 10correlated with Breslow thickness and Clark’s Level [22].
Although the effect of SOCS1 or other SOCS family
members (i.e. SOCS3) on IFN-a-responsiveness of mela-
noma cells was not evaluated in this prior study, our
observations suggest that SOCS1 and SOCS3 could be a
clinically relevant inhibitor of cytokine action.
In contrast to data from our group and others [38],
Kovarik et al. did not observe basal or IFN-a-induced
SOCS3 expression in human melanoma [25]. These dif-
ferences could simply reflect the fact that unique panels
of human melanoma cell lines were used in the two
separate reports. Importantly, the majority of cell lines
used in the present study were derived from metastatic
melanoma lesions, while the study by Kovarik et al.u t i -
lized many less-aggressive, radial-growth phase cell lines
derived from primary melanomas. The lack of IFN-a-
induced SOCS3 expression in the study by Kovarik et
al. could also be attributed to the fact that a majority of
their data was obtained following only a 30 minute sti-
mulation with IFN-a in vitro, and longer (4 hour) IFN-
a stimulation was only reported in two cell lines [25].
Together, these data suggest that SOCS3 expression
Figure 4 Reduced IFN-stimulated gene expression in melanoma cells over-expressing SOCS1 and SOCS3. Transcript levels of the IFN-a-
responsive genes (a) ISG-15, (b) OAS-1, and (c) IFIT2 were measured following a 4 hour stimulation of SOCS1- and SOCS3-over-expressing cell
lines with IFN-a (10
4 U/mL) by Real Time PCR. (d) Transcript levels of the IFN-g-responsive gene IRF1 was also measured in the cell lines
following a 4 hour stimulation with 1 ng/mL IFN-g. All data were normalized to b-actin (housekeeping gene) and expressed relative to PBS-
treated cells. * Denotes p < 0.05 as compared to empty vector transduced cells.
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melanoma tumors. In support of this argument is
another observation that prolonged cultivation of mela-
noma cells has been reported to lead to an increase in
the constitutive expression of SOCS3 transcripts in vitro
[23]. Finally, and in agreement with our data, studies
conducted by other groups have also shown that basal
SOCS3 expression was detectable at the transcript and
protein level in the metastatic A375 melanoma cell line
[24]. Together these data highlight the phenotypic het-
erogeneity of melanoma and indicate the variable biolo-
gic responsiveness of this problematic malignancy.
A role for SOCS proteins in tumor resistance to cyto-
kines has also been suggested in the setting of hemato-
logic malignancy. For example, Sakai et al.
demonstrated that constitutive expression of SOCS3
affected the IFN-a sensitivity of chronic myelogenous
leukemia (CML) cell lines and blast cells from patients
in CML blast crisis [39], while Brender et al.
demonstrated that SOCS3 protected T cell lymphoma
cells against growth inhibition by IFN-a [40]. Other
reports have demonstrated that silencing of SOCS1 can
enhance the anti-tumor activity of type I or type II IFNs
by regulating apoptosis in neuroendocrine tumor cells
[41]. Silencing of SOCS1 also enhanced the anti-prolif-
erative effects of IFNs on the murine B16 and Colon26
cell lines [42]. The present study provides further evi-
dence for the ability of SOCS proteins to regulate the
IFN-responsiveness of melanoma cells.
In the present study, over-expression of SOCS1 signif-
icantly inhibited IFN-responsiveness of melanoma cells
and conversely siRNA-mediated reduction of SOCS1
enhanced the IFN-response. Based on these results
alone, the relative role each individual SOCS protein
plays in regulating the IFN-response in melanoma cells
remains unclear and is likely variable between patients.
Furthermore, the profile of other negative regulatory
proteins is complex, and in theory could compensate
Figure 5 siRNA-mediated reduction of SOCS1 and SOCS3 enhances IFN-responsiveness of melanoma cells. Real Time PCR was used to
validate reduced expression of (a) SOCS1 and (b) SOCS3 48 hours following transient transfection of 1259 MEL cells with empty pSilencer vector
(Control) or pSilencer expressing SOCS-specific siRNA. Data were normalized to b-actin (housekeeping gene) and expressed as mean expression
values relative to cells transfected with control vector. (c) P-STAT1 levels were measured following a 15 minute stimulation of melanoma cells
with IFN-a (10
4 U/mL) or IFN-g (1 ng/mL) by flow cytometry. PBS (vehicle) treated cells served as negative controls. Data represent the mean Fsp
values (± standard deviation) from n = 2 experiments with similar results. (d) IFN-stimulated gene expression was evaluated in response to a 4
hour treatment with IFN-a (10
4 U/mL) 48 hours post-transfection with empty vector (negative control) or vector expressing SOCS1- or SOCS3-
specific siRNA. Data were normalized to b-actin and expressed relative to PBS-treated cells. * Denotes p < 0.05 as compared to empty vector
transfected cells.
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cytokine responsiveness in the cell. An intriguing study
by Huang et al. highlights the controversial role of
SOCS1 protein in the setting of melanoma. In this
report, the authors used an experimental model of A375
melanoma that metastasizes to the brain and demon-
strated that SOCS1 expression is significantly reduced in
brain metastases as compared to the original tumor
[43]. The authors later show that this loss of SOCS1
expression is a critical event leading to elevated STAT3
signaling and over-expression of factors that promote
cellular invasion and angiogenesis. These data caution
that modulating SOCS1 expression as a therapeutic
strategy also has the potential to promote metastasis via
STAT3 and this possibility should be carefully investi-
gated in pre-clinical studies.
The inhibition of negative regulatory pathways to
enhance the anti-tumor effects of cytokines represents a
potentially novel approach against malignancy. Prior
observations have primarily focused on inhibition of
SOCS proteins in immune cells to allow for a greater
anti-tumor effect. For example, Shen et al. have demon-
s t r a t e dt h a ts i l e n c i n go fS O C S 1b ys i R N Ai nd e n d r i t i c
cells used as a therapeutic vaccine strategy resulted in
superior anti-tumor activity in a murine B16F10 model
of melanoma [44]. Our laboratory has also demonstrated
that exogenously administered IFN-a induced profound
in vivo anti-tumor activity that was immune-mediated
(via CD8+ T cells) in SOCS1 and SOCS3 deficient mice
[31]. Data from the present study have expanded our
understanding of SOCS protein expression in melanoma
and suggest that SOCS1 and SOCS3 proteins within the
tumoral compartment represent a potential target that
deserves investigation in future pre-clinical studies.
Conclusions
The present data suggest that SOCS1 and SOCS3 pro-
teins represent a means by which melanoma cells can
evade the direct effects of IFN-a and IFN-g. The role for
intratumoral SOCS1 and SOCS3 proteins as novel thera-
peutic targets remains deserves further evaluation in pre-
clinical studies of melanoma or other malignancies.
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